Real-world evidence on the use of GLP1 receptor agonists

Special issue dedicated to the role of GLP1 receptor agonists (RA) in the treatment of obesity and beyond highlighting real-world data from clinical practice. The efficacy, safety and outcomes of GLP1 RA treatments in diverse patient populations are addressed, examining how these therapies are utilized beyond clinical trials and exploring effects beyond obesity. By showcasing practical insights and patient experiences, this issue aims to enrich our understanding of GLP1 RAs in real-world settings and their potential impact on the management of obesity and other conditions.